Get a reply from this employer — a resume and cover letter tailored to exactly what they’re hiring for.
Providence Medical Technology, Inc. is hiring an Associate Territory Manager in Alabama to support sales initiatives in the medical device industry. This role is pivotal for driving product knowledge and supporting prospect surgeons through training sessions.
Ideal candidates will have over a year of sales experience, preferably in healthcare, along with strong interpersonal and problem-solving skills. The position involves significant travel and developing sales meetings with new surgeons.
Join us in advancing cervical fusion standards and improving patient outcomes.
You must have one (1) + years in SALES, healthcare, or the Medical Device industry to be considered for this role. Local candidates only.
Providence Medical Technology, Inc. is a privately‑held medical device company focused on innovation solutions for cervical spine conditions. The company has pioneered a proprietary approach to posterior cervical fusion and has developed surgical instrumentation and implants that offer unique benefits to the $2 billion worldwide cervical spine market.
Our purpose is to improve clinical outcomes for high‑risk patients and prevent surgical failures of the cervical spine.
LOCATION
We are currently hiring Territory Managers in Alabama.
The Associate Territory Manager (ATM) will work with a Senior Territory Manager (STM) to gain experience in Providence Medical Technology (PMT) product offerings. With the support of their manager, Associates will learn to execute the PMT sales process with the goal of setting meetings with new prospect surgeons, provide training and support, and move them to new users of Corus. This hands‑on case coverage and selling development skills training will last approximately 12–18 months. From there, the Area Sales Manager (ASM) and Sr TM will discuss territory growth options with the associate.
Our Mission is to establish Circumferential Cervical Fusion (CCF) as the standard of care for high‑risk patients.